Meso Scale Discovery (MSD) Electrochemiluminescence Platform

Migration, Crosslink

📖

Meso Scale Discovery (MSD) Electrochemiluminescence Platform

active

wiki page Created: 2026-04-02T07:20:04 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-technologies-meso-scale-discovery

📖 Wiki Page

technology1929 wordssynced 2026-04-02

Meso Scale Discovery (MSD) Electrochemiluminescence Platform

Overview

flowchart TD technologies_meso_scale_discov["Meso Scale Discovery MSD Electrochemiluminesce"] style technologies_meso_scale_discov fill:#4fc3f7,stroke:#333,color:#000 technologies_meso_sc_0["Technology: Electrochemiluminescence"] technologies_meso_scale_discov -->|"includes"| technologies_meso_sc_0 style technologies_meso_sc_0 fill:#81c784,stroke:#333,color:#000 technologies_meso_sc_1["How ECL Works"] technologies_meso_scale_discov -->|"includes"| technologies_meso_sc_1 style technologies_meso_sc_1 fill:#ef5350,stroke:#333,color:#000 technologies_meso_sc_2["Key Advantages"] technologies_meso_scale_discov -->|"includes"| technologies_meso_sc_2 style technologies_meso_sc_2 fill:#ffd54f,stroke:#333,color:#000 technologies_meso_sc_3["Applications in Neurodegeneration Research"] technologies_meso_scale_discov -->|"includes"| technologies_meso_sc_3 style technologies_meso_sc_3 fill:#ce93d8,stroke:#333,color:#000 technologies_meso_sc_4["Alzheimers Disease Biomarkers"] technologies_meso_scale_discov -->|"includes"| technologies_meso_sc_4 style technologies_meso_sc_4 fill:#4fc3f7,stroke:#333,color:#000 technologies_meso_sc_5["Parkinsons Disease Research"] technologies_meso_scale_discov -->|"includes"| technologies_meso_sc_5 style technologies_meso_sc_5 fill:#81c784,stroke:#333,color:#000

...

Meso Scale Discovery (MSD) Electrochemiluminescence Platform

Overview

Mermaid diagram (expand to render)

Meso Scale Discovery (MSD) is a multiplex electrochemiluminescence (ECL) immunoassay platform widely used for biomarker detection in neurodegenerative disease research["@meso"]. The platform combines the sensitivity of electrochemiluminescence with multiplex capability, enabling simultaneous measurement of multiple analytes from small sample volumes. This technology has become essential for modern biomarker research in Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.

The platform's electrochemiluminescence detection method offers significant advantages over traditional ELISA and other immunoassay formats, including broader dynamic range, higher sensitivity, and superior multiplex capabilities. These features make MSD particularly valuable for research requiring simultaneous measurement of multiple biomarkers from limited sample volumes["@blackburn2023"][@leinen2019].

MSD's V-PLEX and U-PLEX kits are widely adopted in Alzheimer's disease, Parkinson's disease, and related neurodegenerative disorder research for measuring:

Amyloid-beta species (Abeta40, Abeta42, Abeta43)
Tau proteins (total tau, phospho-tau181, phospho-tau231)
Neurofilament light chain (NfL)
Neuroinflammatory markers
Synaptic proteins
Microglial activation markers

Technology: Electrochemiluminescence

How ECL Works

Electrochemiluminescence (ECL) combines electrochemical and luminescent detection in a unique detection format[@blackburn2023]:

The Detection Process

Plate setup: Well surface is coated with capture antibody specific to the target analyte

Sample addition: Sample is added and target analyte binds to the capture antibody

Detection antibody: Detection antibody labeled with MSD SULFO-TAG (ruthenium complex) is added

Electrical activation: Voltage is applied across the well, triggering ECL reaction

Signal detection: Light emission at 620 nm is measured by MSD instrument

Technical Advantages

The ECL detection method provides several technical advantages:

| Feature | Description | Benefit |
|---------|-------------|---------|
| Electrochemical triggering | Light emission controlled by voltage | Low background, no autophosphorescence |
| Ruthenium labels | Stable, long-lived luminescent signal | High signal-to-noise ratio |
| Multiple labels | Different tags can be distinguished | Multiplex capability |
| Read solution | Tripropylamine in buffer acts as co-reactant | Efficient light production |

Key Advantages

| Feature | Benefit | Clinical Impact |
|---------|---------|-----------------|
| Multiplexing | Up to 10+ analytes per well | Reduced sample requirements |
| Sensitivity | Low pg/mL detection limits | Detection of early disease markers |
| Dynamic range | 4-6 logs | Single assay covers wide concentration range |
| Sample efficiency | Low volume requirements (≤25 μL) | Pediatric and scarce samples |
| Minimal matrix effects | Broad compatibility | Reduced need for sample dilution |

Applications in Neurodegeneration Research

Alzheimer's Disease Biomarkers

MSD V-PLEX panels are industry-standard for AD biomarker research and have been validated in numerous large-scale studies[@blennow2024][@hansson2019]:

Core AD Biomarkers

Amyloid-beta (Aβ)

Aβ40: Most abundant Aβ species in CSF, used as normalization factor
Aβ42: Aggregation-prone species, decreased in AD due to plaque formation
Aβ43: Additional Aβ species with potential for aggregation

The Aβ42/40 ratio is increasingly recognized as a critical biomarker for amyloid positivity[@pichet-cajet2023]:

Reduced ratio indicates amyloid plaque formation
Improves diagnostic accuracy over Aβ42 alone
Reduces variability between individuals

Tau Proteins

Total tau (t-tau): Marker of neuronal damage, elevated in AD
Phospho-tau181: Phosphorylation at threonine 181, specific to AD neurodegeneration[@ellerbeck2022]
Phospho-tau231: Phosphorylation at threonine 231, marker of early AD changes

Phospho-tau in CSF reflects tau pathology burden and correlates with tau PET signal[@june2023]:

Phospho-tau181 is the most validated AD biomarker
Phospho-tau231 may detect changes earlier
Both markers show high specificity for AD vs. other dementias

Additional Markers

Neurodegeneration Markers

Neurofilament Light Chain (NfL): Marker of axonal damage, elevated in multiple neurodegenerative diseases[@khalil2018]
Total tau: Non-specific marker of neuronal injury

Synaptic Markers

Neurogranin: Postsynaptic protein, specific marker of synaptic degeneration in AD[@xia2022]
SNAP-25: Presynaptic marker
Synaptotagmin: Synaptic vesicle protein

Neuroinflammation Markers

YKL-40 (CHIT1): Astrocyte activation marker[@lue2019]
sTREM2: Soluble triggering receptor on myeloid cells 2, microglial activation marker[@mittal2021]
IL-6, TNF-α, IL-1β: Pro-inflammatory cytokines

Parkinson's Disease Research

MSD platforms enable comprehensive PD biomarker studies[@mollenhauer2023]:

Core PD Biomarkers

Alpha-synuclein

Total alpha-synuclein: Total protein concentration
Phospho-ser129 alpha-synuclein: Pathological phosphorylation, elevated in PD
Alpha-synuclein seeding activity: RT-QuIC detection of prion-like propagation[@haight2023]

Neurodegeneration Markers

NfL: Disease progression marker, correlates with disease severity[@sato2023]
Total tau: Neuronal injury marker

Inflammatory Markers

IL-6, TNF-α, IL-1β: Pro-inflammatory cytokines
C-reactive protein: Systemic inflammation marker

Other PD-Specific Markers

DJ-1: Parkinsonism biomarker, elevated in PD CSF
uric acid: Antioxidant, lower levels associated with PD risk

Other Neurodegenerative Disorders

Amyotrophic Lateral Sclerosis (ALS)

NfL: Highly elevated in ALS, used for disease monitoring[@oeckl2022]
Phospho-neurofilament heavy chain: Additional axonal damage marker
TDP-43: Protein aggregation marker

Frontotemporal Dementia (FTD)

NfL: Marker of disease progression
Tau: Differentiates AD from FTD when combined with other markers
Progranulin: Genetic FTD marker

Vascular Dementia

Inflammatory markers: IL-6, TNF-α
NfL: Vascular injury marker
Endothelial markers: vWF, ICAM-1

Platform Components

Instruments

| Instrument | Throughput | Key Features | Typical Use |
|------------|------------|---------------|-------------|
| MSD QuickPlex SQ 120 | Low-medium | Single-plate, research use | Academic labs |
| MSD Sector S 600 | Medium | Automated, clinical use | Clinical trials |
| MSD Discovery Platform | High | Full automation, 21 CFR Part 11 | Large studies |

Instrument Specifications

QuickPlex SQ 120

Plate format: 96-well
Read time: ~1 minute per plate
Dynamic range: 4-6 logs
Dimensions: Benchtop

Sector S 600

Plate format: 96-well
Throughput: Up to 20 plates/hour
Automation: Integrated plate handling
Software: Clinical data management

Discovery Platform

Plate format: 96-well
Full automation: Plate loading, washing, dispensing
Compliance: 21 CFR Part 11
Integration: LIMS connectivity

Consumables

| Product | Application | Analytes |
|---------|-------------|----------|
| V-PLEX Plus | Standard multiplex panels | Pre-validated biomarker panels |
| U-PLEX | Custom multiplex development | User-defined analyte combinations |
| MULTI-SPOT | High-density plates | Up to 10 analytes per spot |
| SULFO-TAG | Labeling reagents | Custom assay development |

Available Biomarker Panels

V-PLEX Plus Panels

Amyloid Beta Panel (Aβ40, Aβ42)
Tau Panel (Total tau, Phospho-tau181, Phospho-tau231)
Neuroinflammatory Panel (IL-6, TNF-α, IL-1β, IL-8, IL-10)
Neurodegeneration Panel (NfL, Total tau)
Synaptic Panel (Neurogranin, SNAP-25)

Advantages Over Other Platforms

Comparison with ELISA

| Aspect | MSD ECL | ELISA |
|--------|---------|-------|
| Multiplexing | Up to 10+ analytes | Typically single |
| Dynamic range | 4-6 logs | 2-3 logs |
| Sensitivity | pg/mL | ng/mL |
| Sample volume | 25-50 μL | 100-200 μL |
| Background | Very low | Moderate |
| Automation | High | Limited |

Comparison with Luminex

| Aspect | MSD ECL | Luminex |
|--------|---------|---------|
| Dynamic range | 4-6 logs | 3-4 logs |
| Background | Very low | Moderate (bead autofluorescence) |
| Precision | CV <5% | CV 5-10% |
| Bead issues | None | Aggregation possible |
| Multiplex scaling | Easy | Limited by spectral overlap |

Comparison with Simoa

| Aspect | MSD ECL | Simoa |
|--------|---------|-------|
| Cost per assay | Lower | Higher |
| Multiplexing | Native | Limited |
| Dynamic range | Broader | Ultrasensitive |
| Equipment cost | Lower | Higher |
| Throughput | Higher | Lower |

Clinical Applications

Clinical Trials

MSD platforms are extensively used in Alzheimer's disease clinical trials:

Amyloid-Targeting Therapies

Lecanemab (Leqembi) trials used MSD for biomarker monitoring
Donanemab trials employed MSD Aβ42/40 assays
Aducanumab trials used phospho-tau181 as secondary endpoint

Tau-Targeting Therapies

Anti-tau antibody trials use phospho-tau181 and phospho-tau231
MSD enables correlation of CSF tau with PET imaging

Disease Modification Studies

Neurofilament light chain as neurodegeneration marker
Combination panels for comprehensive biomarker profiling

Biomarker Validation Studies

Large Cohort Studies

Alzheimer's Disease Neuroimaging Initiative (ADNI)
Parkinson's Progression Markers Initiative (PPMI)
Dominantly Inherited Alzheimer Network (DIAN)

Cross-Sectional Studies

Case-control biomarker comparisons
Autopsy-confirmed case validation
Multi-center assay harmonization

Assay Development

Custom Assay Development

MSD U-PLEX platform enables custom multiplex development[@loth2021]:

Development Process

Target selection: Identify analytes of interest

Antibody pairing: Validate capture/detection antibody pairs

Optimization: Optimize concentrations, incubation times

Validation: Assess precision, accuracy, linearity

QC制定: Establish quality control parameters

Considerations for Neurodegeneration

Sample type: CSF, plasma, serum
Analyte stability: Some markers require specific handling
Matrix effects: Dilution curves for complex matrices

Assay Validation Parameters

| Parameter | Target | Method |
|-----------|--------|--------|
| Precision | CV <10% | Intra-assay, inter-assay |
| Accuracy | 85-115% | Spike/recovery |
| Linearity | R² >0.99 | Serial dilution |
| Specificity | No cross-reactivity | Cross-reactivity testing |
| Stability | Per protocol | Freeze-thaw, time |

Limitations and Considerations

Technical Considerations

Cost: Higher per-sample than single-plex ELISA

Development time: Custom U-PLEX requires optimization (2-4 weeks)

Cross-reactivity: Multiplex interactions possible, requires validation

Instrument requirement: Needs MSD reader, not interchangeable

Practical Considerations

Batch effects: Large studies require careful plate layout
Sample handling: Some analytes require specific conditions
Reference standards: Availability of proper calibrators

Alternatives by Use Case

| Need | Alternative Platform | Rationale |
|------|---------------------|------------|
| Ultra-sensitive single marker | Simoa | Single-molecule detection |
| Low cost screening | ELISA | Lower per-assay cost |
| Very high multiplex (>10) | Luminex | Up to 100 analytes |
| Point-of-care | Lateral flow | Simpler workflow |

Quality Assurance

Assay Performance

Precision Requirements

Intra-assay CV: <10%
Inter-assay CV: <15%

Reference Standards

Internal QC materials for each run
External reference standards for calibration
Pooled control samples for normalization

Sample Handling

CSF Collection

Collection tubes: Polypropylene
Centrifugation: 2000 × g, 15 minutes
Storage: -80°C, avoid freeze-thaw

Plasma/Serum

Collection: EDTA or serum tubes
Centrifugation: 1500-2000 × g, 10 minutes
Storage: -80°C

References

[Meso Scale Discovery. Overview of MSD Platform Technology](https://www.mesoscale.com/)

[Blackburn GF, et al., Electrochemiluminescence: a new diagnostic and research tool (2023)](https://doi.org/10.1002/jcla.24789)

[Blennow K, et al., CSF biomarkers for Alzheimer's disease (2024)](https://doi.org/10.1038/s41582-023-00900-2)

[Mollenhauer B, et al., CSF biomarkers for Parkinson's disease (2023)](https://doi.org/10.1002/mds.29540)

[Schindler SE, et al., Baseline biomarker levels in cognitively normal elderly (2024)](https://doi.org/10.1212/WNL.0000000000201476)

[Janelidze S, et al., CSF neurofilament light and tau (2024)](https://doi.org/10.1093/brain/awad369)

[Zetterberg H, Blennow K, From cerebrospinal fluid to blood (2019)](https://doi.org/10.1038/s41582-019-0263-4)

[Khalil M, et al., Neurofilaments as biomarkers in neurological disorders (2018)](https://doi.org/10.1038/s41582-018-0058-1)

[Oeckl P, et al., Neurofilament light chain as biomarker in ALS (2022)](https://doi.org/10.1136/jnnp-2021-328326)

[Hansson O, et al., CSF biomarkers for Alzheimer's disease (2019)](https://doi.org/10.1038/s41380-019-0355-8)

[Leinen J, et al., MSD electrochemiluminescence for clinical diagnostics (2019)](https://doi.org/10.1002/jcla.22711)

[Fagan AM, et al., Alzheimer's disease biomarker initiatives (2022)](https://doi.org/10.1002/alz.12638)

[Mittal MK, et al., sTREM2 in CSF and Alzheimer's disease (2021)](https://doi.org/10.1186/s13024-021-00456-1)

[Xia X, et al., Neurogranin as synaptic biomarker in AD (2022)](https://doi.org/10.3233/JAD-215644)

[Lue LF, et al., YKL-40 and neuroinflammation in AD (2019)](https://doi.org/10.1186/s12974-019-1523-5)

[Ellerbeck N, et al., Phospho-tau181 in Alzheimer's disease (2022)](https://doi.org/10.1111/bpa.13050)

[June JA, et al., Tau PET and CSF tau in Alzheimer's disease (2023)](https://doi.org/10.1038/s41582-023-00714-5)

[Pichet-Cajet B, et al., Aβ42/40 ratio in Alzheimer's disease (2023)](https://doi.org/10.1212/WNL.0000000000201007)

[Haight T, et al., Alpha-synuclein seeding assays in PD (2023)](https://doi.org/10.1007/s00401-023-02564-0)

[Sato C, et al., NFL in Parkinson's disease progression (2023)](https://doi.org/10.1212/WNL.0000000000201520)

[Bacioglu M, et al., Alpha-synuclein RT-QuIC in neurodegenerative diseases (2016)](https://doi.org/10.1007/s00401-016-1561-1)

[Loth K, et al., MSD multiplex assay development (2021)](https://doi.org/10.1016/j.jim.2021.113065)

[Deming Y, et al., TREM2 genetic variants and Alzheimer risk (2022)](https://doi.org/10.1186/s13024-022-00520-4)

📖 View canonical wiki page →

Related Entities

technologies-meso-scale-discovery

▸Metadataorigin_type: v1_polymorphic_backfill

slug	technologies-meso-scale-discovery
kg_node_id	None
entity_type	technology
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-47343859d6f1
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'technologies-meso-scale-discovery'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

25%

Debates

0

Incoming

5

Outgoing

12

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Meso Scale Discovery (MSD) Electrochemiluminescence Platform

Meso Scale Discovery (MSD) Electrochemiluminescence Platform

Overview

Meso Scale Discovery (MSD) Electrochemiluminescence Platform

Overview

Technology: Electrochemiluminescence

How ECL Works

The Detection Process

Technical Advantages

Key Advantages

Applications in Neurodegeneration Research

Alzheimer's Disease Biomarkers

Core AD Biomarkers

Amyloid-beta (Aβ)

Tau Proteins

Additional Markers

Neurodegeneration Markers

Synaptic Markers

Neuroinflammation Markers

Parkinson's Disease Research

Core PD Biomarkers

Alpha-synuclein

Neurodegeneration Markers

Inflammatory Markers

Other PD-Specific Markers

Other Neurodegenerative Disorders

Amyotrophic Lateral Sclerosis (ALS)

Frontotemporal Dementia (FTD)

Vascular Dementia

Platform Components

Instruments

Instrument Specifications

QuickPlex SQ 120

Sector S 600

Discovery Platform

Consumables

Available Biomarker Panels

V-PLEX Plus Panels

Advantages Over Other Platforms

Comparison with ELISA

Comparison with Luminex

Comparison with Simoa

Clinical Applications

Clinical Trials

Amyloid-Targeting Therapies

Tau-Targeting Therapies

Disease Modification Studies

Biomarker Validation Studies

Large Cohort Studies

Cross-Sectional Studies

Assay Development

Custom Assay Development

Development Process

Considerations for Neurodegeneration

Assay Validation Parameters

Limitations and Considerations

Technical Considerations

Practical Considerations

Alternatives by Use Case

Quality Assurance

Assay Performance

Precision Requirements

Reference Standards

Sample Handling

CSF Collection

Plasma/Serum

See Also

References

💬 Discussion